06 June, 2017
Usually the RSI is considered overbought when above 70 and oversold when less than 30.
Other research analysts have also issued research reports about the company. Guggenheim reaffirmed an "outperform" rating and set a $10.00 price target on shares of Synergy Pharmaceuticals in a research report on Thursday, March 2nd. Similarly, the company's last 5 years high P/E ratio is 0 and low P/E is 0, whereas, the industry's and sector's high P/E for the past year is 237.16 and 43.55 respectively and low P/E ratio for the last 5 years is 83.26 for the industry and 23.18 for the Sector. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned "Buy" rating by TH Capital on Thursday, October 29. HC Wainwright set a $18.00 target price on Synergy Pharmaceuticals and gave the company a "buy" rating in a report on Friday, January 27th. Synergy Pharmaceuticals presently has an average rating of "Buy" and an average price target of $11.50.
05/15/2017 - Synergy Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at Rodman & Renshaw. A rating of 3 would signify a consensus Hold recommendation.
Williams Jones And Associate Ltd Limited Liability Company owns 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 11,000 shares. The firm's market capitalization is $913.29 million. Synergy Pharmaceuticals has a one year low of $3.34 and a one year high of $7.15. The share price has moved backward from its 20 days moving average -2.26% and negatively from its 50 days moving average -9.99%.
Over the last 5 years, Synergy Pharmaceuticals Inc. has averaged a -31.80% YoY EPS growth rate. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.07. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.10 million. On average, equities analysts expect that Synergy Pharmaceuticals will post ($0.91) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & worldwide copyright and trademark law.
Synergy Pharmaceuticals, Inc. (SGYP) has been given an average price target of $10.44 from analysts, according to data collected by Finviz. The company's stock had a trading volume of 18,455,490 shares. State Street Corp boosted its position in shares of Synergy Pharmaceuticals by 11.6% in the fourth quarter. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Asymmetry Capital Management L.P. now owns 339,068 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 40,878 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in Synergy Pharmaceuticals by 32.5% in the third quarter. State Street Corp now owns 6,283,669 shares of the biopharmaceutical company's stock valued at $38,270,000 after buying an additional 653,353 shares in the last quarter. Swiss National Bank boosted its stake in Synergy Pharmaceuticals by 67.8% in the third quarter. Pacad Investment Ltd. now owns 217,283 shares of the biopharmaceutical company's stock worth $1,323,000 after buying an additional 189,183 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in shares of Synergy Pharmaceuticals during the fourth quarter valued at about $146,700,000.
Large investors have recently modified their holdings of the company. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/06/06/2-82-million-in-sales-expected-for-synergy-pharmaceuticals-inc-sgyp-this-quarter.html. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide.